Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients

BackgroundStage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma and several studies have also shown their benefit i...

Descripció completa

Dades bibliogràfiques

Autors principals:	Francesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, Giulia Poti, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Roberto Morese, Zorika Christiana Di Rocco, Gabriele Piesco, Paolo Chesi, Cristina Maria Failla, Paolo Marchetti, Federica De Galitiis
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-08-01
Col·lecció:	Frontiers in Oncology
Matèries:	melanoma adjuvant immunotherapy anti-PD-1 hyperprogression disease molecular profiling
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1437325/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!